The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
The meaning of p16ink4aexpression in tumors: Functional significance, clinical associations and future developments
Open accessAbstract
The CDKN2A gene is a tumor suppressor that encodes the CDK4/6 inhibitor p16(ink4a). Loss of this tumor suppressor contributes to the bypass of critical senescent signals and is associated with progression to malignant disease. However, the high-level expression of p16(ink4a) in tumors is associated with aggressive subtypes of disease, and in certain clinical settings elevated p16(ink4a) expression is an important determinant for disease prognosis and therapeutic response. These seemingly contradictory facets of p16(ink4a) expression have lead to confusion related to the meaning of this tumor suppression in tumor pathobiology. As reviewed here, the alternative expression of p16(ink4a) represents an ideal marker for considering RB-pathway function, tumor heterogeneity, and novel means for directing therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In agreement with p16's role as a guardian of senescence, mutations, silencing or loss of CDKN2A, the gene encoding p16, facilitate senescence bypass and it is frequently associated with carcinogenesis (reviewed in.51,52”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R. H., Weber, R. S., Rosenthal, D. I., Nguyen‐Tan, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C. S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,573
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“The p16 protein was identified as a low molecular weight protein bound to cyclin dependent kinase 4 and 6 (CDK4 and CDK6).(1,2) This biochemical characterization was largely facilitated by the finding that in tumor cells transformed by SV40 the sole form of CDK4 that was detectable was in complex with p16.”
BackgroundThe human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Fakhry, C., Westra, W. H., Li, S., Cmelak, A. J., Ridge, J. A., Pinto, H. A., Forastiere, A. A., & Gillison, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn011 · Cited by 2,777
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 1×
“Initially, it was observed that the gene encoding CDKN2A was mutated or silenced in a wide spectrum of tumor types and cell lines.(20,21) Particularly, loss or epigenetic silencing of CDKN2A is very common in cell lines, suggesting that the process of cell culture selects against the expression of p16.”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Research works printed but not linked: 7
- Sherr CJ, 2000, Harvey Lect, 96, 73
- Sherr CJ, 1992, Ciba Found Symp, 170, 209
- de Jonge HJ, 2009, Aging (Albany, NY Online), 1, 949
- Hruban RH, 2000, Clin Cancer Res, 6, 2969
- Henshall SM, 2001, Clin Cancer Res, 7, 544
- Otterson GA, 1994, Oncogene, 9, 3375
- Lee CT, 1999, Clin Cancer Res, 5, 977
Cited by
Sorted by citations
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationForging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“Limitations include poor detection of p16INK4a in mice by the currently available antibodies using immunohistochemistry [79], as well as some situations, where p16INK4a levels are increased, in the absence of other signs of cellular senescence [81,83,84].”
BackgroundA multidimensional systems biology analysis of cellular senescence in aging and disease
Avelar, R. A., Ortega, J. G., Tacutu, R., Tyler, E. J., Bennett, D., Binetti, P., Budovsky, A., Chatsirisupachai, K., Johnson, E., Murray, A., et al. (2020) · Genome Biology · doi:10.1186/s13059-020-01990-9 · Cited by 399
Metadata
- Authors
- Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2011-08
- Volume
- 10
- Issue
- 15
- Pages
- 2497-2503
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC3685613
- OpenAlex
- W2019517928
- Cited by
- 286
- References
- 62
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 14 · 2023: 22 · 2022: 29 · 2021: 16 · 2020: 26 · 2019: 26 · 2018: 24 · 2017: 18 · 2016: 13 · 2015: 19 · 2014: 14 · 2013: 19 · 2012: 10
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA099996)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p16INK4a, CDKN2A, tumor suppressor, Rb pathway, cellular senescence, tumor heterogeneity, prognosis, treatment response, tumor progression, CDK4/6 inhibition
- MeSH terms
- Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Retinoblastoma Protein, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
